development of heterogeneous glycopeptide-intermediate (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant endocarditis Free

Abstract

We report a patient who developed a meticillin-resistant (MRSA) central venous catheter infection complicated by infective endocarditis. The patient was initially treated with glycopeptides, which led to the development of heterogeneous glycopeptide resistance, the detection of which required the use of a macro Etest screening test. Subsequently, the causative strain, confirmed by PFGE as a UK epidemic MRSA-15, was treated with daptomycin, and again resistance developed . The development of resistance to both these agents suggests that the resistance mechanisms may be associated. We suggest that the clinician managing MRSA infection should anticipate daptomycin resistance when reduced glycopeptide susceptibility is detected.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.006486-0
2009-03-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/3/376.html?itemId=/content/journal/jmm/10.1099/jmm.0.006486-0&mimeType=html&fmt=ahah

References

  1. Boyle-Vavra S., Berke S. K., Lee J. C., Daum R. S. 2000; Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 44:272–277 [CrossRef]
    [Google Scholar]
  2. British Society for Antimicrobial Chemotherapy; 2007; Methods for Antimicrobial Susceptibility Testing . Version 7 http://www.bsac.org.uk/susceptibility_testing/bsac_standardized_disc_susceptibility_method.cfm
  3. Cui L., Ma X., Sato K., Okuma K., Tenover F. C., Mamizuka E. M., Gemmell C. G., Kim M.-N., Ploy M.-C. other authors 2003; Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus . J Clin Microbiol 41:5–14 [CrossRef]
    [Google Scholar]
  4. Falagas M. E., Makris G. C., Dimopoulos G., Matthaiou D. K. 2008; Heteroresistance: a concern of increasing clinical significance?. Clin Microbiol Infect 14:101–104 [CrossRef]
    [Google Scholar]
  5. Hayden M. K., Rezai K., Hayes R. A., Lolans K., Quinn J. P., Weinstein R. A. 2005; Development of daptomycin resistance in vivo in methicillin resistant Staphylococcus aureus . J Clin Microbiol 43:5285–5287 [CrossRef]
    [Google Scholar]
  6. Jones T., Yeaman M. R., Sakoulas G., Yang S. J., Proctor R. A. 2008; Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry and drug binding. Antimicrob Agents Chemother 52:269–278 [CrossRef]
    [Google Scholar]
  7. Murchan S., Kaufmann M. E., Deplano A., de Ryck R., Struelens M., Zinn C. E., Fussing V., Salmenlinna S., Vuopio-Varkila J. other authors 2003; Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus : a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol 41:1574–1585 [CrossRef]
    [Google Scholar]
  8. Neoh H. M., Cui L., Yuzawa H., Takeuchi F., Matsuo M., Hiramatsu K. 2008; Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 52:45–53 [CrossRef]
    [Google Scholar]
  9. Patel J. B., Jevitt L. A., Hageman J., McDonald L. C., Tenover F. C. 2006; An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus . Clin Infect Dis 42:1652–1653 [CrossRef]
    [Google Scholar]
  10. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R. C., Eliopoulos G. M. 2006; Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581–1585 [CrossRef]
    [Google Scholar]
  11. Sharma M., Riederer K., Chase P., Khatib R. 2008; High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 27:433–437 [CrossRef]
    [Google Scholar]
  12. Silverman J. A., Perlmutter N. G., Shapiro H. M. 2003; Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus . Antimicrob Agents Chemother 47:2538–2544 [CrossRef]
    [Google Scholar]
  13. Vikram H. R., Havill N. L., Koeth L. M., Boyce J. M. 2005; Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43:5384–5387 [CrossRef]
    [Google Scholar]
  14. Voss A., Mouton J. W., van Elzakker E. P., Hendrix R. G., Goessens W., Kluytmans J. A., Krabbe P. F., de Neeling H. J., Sloos J. H. other authors 2007; A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 6:9 [CrossRef]
    [Google Scholar]
  15. Wootton M., Howe R. A., Hillman R., Walsh T. R., Bennett P. M., MacGowan A. P. 2001; A modified population analysis profile method to detect Staphylococcus aureus with decreased susceptibilities to vancomycin in a UK hospital. J Antimicrob Chemother 47:399–404 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.006486-0
Loading
/content/journal/jmm/10.1099/jmm.0.006486-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed